PAI
PTCT icon

Palo Alto Investors’s PTC Therapeutics PTCT Stock Holding History

Palo Alto Investors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$75M Sell
918,846
-2,761
-0.3% -$199K 10.36% 1
2026
Q1 		$62.8M Buy
921,607
+17,691
+2% +$1.25M 9.6% 3
2025
Q4 		$68.7M Buy
903,916
+41,303
+5% +$3M 9.56% 3
2025
Q3 		$52.9M Buy
862,613
+456,144
+112% +$23.8M 9.8% 2
2025
Q2 		$19.9M Buy
406,469
+2,273
+0.6% +$108K 4.22% 8
2025
Q1 		$20.6M Buy
404,196
+17,783
+5% +$887K 3.92% 8
2024
Q4 		$17.4M Buy
386,413
+121,944
+46% +$5.22M 2.7% 13
2024
Q3 		$9.81M Buy
+264,469
New +$8.85M 1.27% 14

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Palo Alto Investors's PTCT Position: Q2 2026 in Review

Palo Alto Investors reduced its PTC Therapeutics (PTCT) stake by 0.3% in Q2 2026, selling an estimated $199K and leaving 918,846 shares worth $75M. The position accounts for 10.36% of the portfolio, ranked #1.

Palo Alto Investors first reported a position in PTCT in Q3 2024 and has held it in 8 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Palo Alto Investors held 918,846 shares of PTC Therapeutics worth $75M as of Q2 2026.
  • Palo Alto Investors sold 2,761 PTC Therapeutics shares in Q2 2026, an estimated $199K.
  • PTC Therapeutics made up 10.36% of Palo Alto Investors's portfolio in Q2 2026, its #1 holding.
  • Palo Alto Investors first reported a position in PTC Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Palo Alto Investors's 13F filing for Q2 2026, filed 17 Aug 2026.